BioSpace News Archive

Plus Therapeutics, Inc. today announced positive data from the ongoing ReSPECT-GBM Phase 2 trial evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM) at the Society for NeuroOncology (SNO) 28th Annual Meeting held November 15-19, 2023 in Vancouver, Canada.

On November 20, 2023 , Viva Biotech Holdings Group (1873. HK) announced that it completed a funding round, securing approximately US$210 million and bringing in the strategic investors, Temasek, Highlight Capital (HLC), and True Light.

Labcorp announced today the completion of the previously announced transaction with Legacy Health to acquire select assets of Legacy’s outreach laboratory business.

On November 20 , 2023, Porton Advanced announced a strategic partnership with Ascle Therapeutics to jointly develop and produce NK cells, assist in the development and innovation in gene and cell therapy, and accelerate the application of NK cells in cancer prevention, beauty, and anti-aging.

OneOncology, the fastest-growing national platform for independent oncology practices, has appointed Ian Flinn , MD, PhD, as Chief Scientific Officer.

Nevro Corp. today announced the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) multicenter randomized controlled trial (RCT) in the Journal of Neurosurgery: Spine.

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.

SAB Biotherapeutics today announced that Katie Ellias has been appointed to the Company’s Board of Directors.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that Blue Cross Blue Shield of Louisiana has joined the growing list of payors reducing the patient eligibility requirements for transcranial magnetic stimulation treatment from four failed medication trials to two.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI ) today announced today the receipt of formal notification from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity.